Related Experiment Video
Updated: Mar 17, 2026
Methods for Detecting Cough and Airway Inflammation in Mice
Published on: August 2, 2024
Inhibition of Airway Epithelial CTSC Attenuates Type 2 Inflammation: Implications for Eosinophilic Chronic
Xiayan Li1, Zhenchao Zhu1, Junlu Zhu2
1Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, People's Republic of China.
Purpose:
Cathepsin C (CTSC) has been identified as a key pathogenic gene in chronic rhinosinusitis. This study aimed to investigate the specific function and subcellular localization of CTSC within the nasal mucosal epithelium.
Patients And Methods:
A total of 34 patients with eosinophilic chronic rhinosinusitis with nasal polyps (eNP), 32 with non-eosinophilic chronic rhinosinusitis with nasal polyps (neNP), and 16 control subjects were enrolled. Airway epithelial morphology was examined by scanning electron microscopy. The expression, localization, and function of CTSC in epithelial cells were assessed using single-cell RNA sequencing (scRNA-seq), immunohistochemistry, quantitative real-time PCR, Western blot, and an siRNA-mediated knockdown approach in an IL-4/IL-13-stimulated 16HBE cell line model.
Results:
scRNA-seq revealed that CTSC was primarily localized to goblet cells and basal cells within the nasal epithelium, with its expression significantly upregulated in eNP patients compared with those in control subjects and neNP. These findings were confirmed at both the RNA and protein levels in clinical tissue samples. CTSC mRNA expression showed a significant positive correlation with the expression of T-helper 2 cytokines, including IL-4 and IL-13. In vitro experiments demonstrated that CTSC expression was induced in 16HBE cells upon IL-4/IL-13 stimulation. siRNA-mediated knockdown of CTSC led to pronounced suppression of IL-4/IL-13-induced release of CCL26, IL-25, and TNF-α, underscoring its functional involvement in inflammatory responses.
Conclusion:
This study identifies CTSC as a novel regulator of type 2 inflammation like eNP. It is specifically upregulated in nasal epithelial goblet and basal cells, highlighting its potential as a therapeutic target for airway diseases.
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...